Blue Earth Therapeutics

Blue Earth Therapeutics is a private, clinical-stage biotech developing precision radiopharmaceuticals for oncology. As part of the Bracco corporate family, it benefits from the strategic and financial support of a major player in medical imaging, which is synergistic with the diagnostic and therapeutic nature of radiopharmaceuticals. The company is advancing a pipeline of targeted radioligand therapies, positioning itself in the rapidly growing field of radiopharmaceuticals which combines targeted molecules with radioactive isotopes to treat cancers. Its headquarters and R&D are based in the Oxford Science Park, a key UK biotech hub.

Targeted radioligand therapy platform combining tumor-targeting molecules with therapeutic radioisotopes.

The targeted radiopharmaceutical field is highly competitive, dominated by Novartis with approved products and a deep pipeline. Other large players like Bayer and AstraZeneca, plus numerous biotechs, are actively developing RLTs. Blue Earth must differentiate through novel targets, improved isotopes/safety, or superior efficacy data.